arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Arrowhead Pharmaceuticals, Inc.

ARWR Health Care Biotechnology: Pharmaceutical Preparations
$58.02
▼ -1.4% Today
as of Oct 23, 16:00 ET
Last 30 days -28.08% Sep 14 → Oct 23
$53.92 $61.10 $68.28 $75.47 $82.65 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$58.06
High
$59.90
Low
$56.97
Volume
$1M
Avg Vol
$2M
Mkt Cap
$12.1B
P/E (TTM)
—
Beta
—
52w High
$95.49
52w Low
$36.73
Div Yield
—
Shares Out
$141M

Recent Press Releases & News last 60 days · 25 items

Oct 16 · 09:09 Simply Wall St.
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
Oct 15 · 15:08 Zacks Small Cap Research
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
Oct 15 · 14:33 MT Newswires
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $109 From $63, Maintains Buy Rating
▸ Show all 25 press releases & news Free account →

ARWR earnings at a glance

The options market is pricing a move of about ±6.2% after the report, a range of roughly $54.44 to $61.60 from today's $58.02. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±4.4% on average; after the most recent report on May 7, 2026 it moved -1.5%. That means options currently expect more movement than ARWR has typically delivered. ARWR beat the consensus EPS estimate in 2 of its last 3 reported quarters. Implied volatility is currently 52%. The share price of $58.02 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$37
$95
36% of range
Avg surprise (last 3)
+1,557%
Avg reaction (last 2)
+2.9%
50% positive
Latest IV / EM
52%
EM ±6.2% · $60 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.39$-0.35$0.68$1.71$2.75 Actual $0.45Actual $-0.96Actual $-1.24Actual $-1.02Actual $-1.38Actual $-1.39Actual $2.75Est $-0.06Actual $-1.26Est $-0.94Actual $0.22Actual $-0.93Est $-1.18Actual $-1.36 MarJunDecMarJunDecMar/2025Jun/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-194M$-3M$188M$379M$570M Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.36 — — — — financials
Thu May 7, 2026Mar/2026 $-0.93 $-1.18 +21.2% -133.8% -1.5% earnings
Wed Dec 31, 2025Dec 2025 $0.22 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.26 $-0.94 -34.0% — — earnings
Mon May 12, 2025Mar/2025 $2.75 $-0.06 +4,683% — +7.2% earnings
Tue Dec 31, 2024Dec 2024 $-1.39 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.38 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.02 — — — — financials
Sun Dec 31, 2023Dec 2023 $-1.24 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.96 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.45 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$75M$74M$264M—$28M$543M$2M—
Cost of revenue————————
Gross profit————————
Operating income$-170M$-141M$41M—$-166M$381M$-161M—
Net income$-194M$-138M$28M—$-175M$368M$-175M—
EPS (diluted)$-1.36$-0.93$0.22—$-1.26$2.75$-1.39—

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents————————
Inventory————————
Total current assets$1.67B$1.84B$1.17B$951M$947M$1.14B$571M$695M
Total assets$2.11B$2.27B$1.60B$1.39B$1.38B$1.57B$1.01B$1.14B
Long-term debt————————
Total liabilities————————
Total equity$466M$599M$563M$466M$520M$684M$56M$185M

Implied volatility — last 90 days

41%55%70%84%98% Jun 07 — IV 78% · EM ±10.8%Jun 08 — IV 76% · EM ±10.0%Jun 09 — IV 70% · EM ±8.8%Jun 10 — IV 75% · EM ±8.9%Jun 11 — IV 74% · EM ±8.1%Jun 12 — IV 70% · EM ±7.1%Jun 15 — IV 62% · EM ±4.5%Jun 16 — IV 58% · EM ±3.4%Jun 17 — IV 83% · EM ±3.5%Jun 19 — IV 58% · EM ±12.9%Jun 22 — IV 53% · EM ±11.0%Jun 23 — IV 60% · EM ±12.2%Jun 24 — IV 55% · EM ±11.0%Jun 25 — IV 55% · EM ±10.8%Jun 26 — IV 58% · EM ±11.1%Jun 29 — IV 56% · EM ±10.0%Jun 30 — IV 55% · EM ±9.4%Jul 01 — IV 58% · EM ±9.7%Jul 02 — IV 58% · EM ±9.4%Jul 03 — IV 60% · EM ±9.4%Jul 06 — IV 65% · EM ±9.1%Jul 07 — IV 65% · EM ±8.6%Jul 08 — IV 62% · EM ±7.8%Jul 09 — IV 68% · EM ±8.0%Jul 10 — IV 71% · EM ±7.8%Jul 13 — IV 85% · EM ±7.1%Jul 14 — IV 78% · EM ±5.7%Jul 15 — IV 70% · EM ±4.1%Jul 16 — IV 95% · EM ±4.0%Jul 20 — IV 79% · EM ±18.7%Jul 21 — IV 76% · EM ±17.6%Jul 22 — IV 65% · EM ±14.9%Jul 23 — IV 54% · EM ±12.1%Jul 24 — IV 56% · EM ±12.4%Jul 27 — IV 61% · EM ±12.8%Jul 28 — IV 60% · EM ±12.2%Jul 29 — IV 63% · EM ±12.6%Jul 30 — IV 65% · EM ±12.7%Jul 31 — IV 65% · EM ±12.5%Aug 03 — IV 68% · EM ±12.0%Aug 04 — IV 60% · EM ±10.4%Aug 05 — IV 55% · EM ±9.2%Aug 06 — IV 46% · EM ±7.4%Aug 07 — IV 49% · EM ±7.7%Aug 10 — IV 55% · EM ±7.6%Aug 11 — IV 49% · EM ±6.5%Aug 12 — IV 47% · EM ±5.9%Aug 13 — IV 45% · EM ±5.3%Aug 14 — IV 48% · EM ±5.3%Aug 17 — IV 65% · EM ±5.5%Aug 18 — IV 46% · EM ±3.3%Aug 19 — IV 66% · EM ±3.9%Aug 20 — IV 48% · EM ±2.0%Aug 24 — IV 50% · EM ±10.5%Aug 25 — IV 49% · EM ±10.1%Aug 26 — IV 48% · EM ±9.6%Aug 27 — IV 45% · EM ±8.8%Aug 28 — IV 48% · EM ±9.1%Aug 31 — IV 43% · EM ±7.7%Sep 01 — IV 50% · EM ±8.6%Sep 02 — IV 52% · EM ±8.7%Sep 03 — IV 51% · EM ±8.2%Sep 04 — IV 41% · EM ±6.4%Sep 07 — IV 46% · EM ±6.4%Sep 08 — IV 51% · EM ±6.7%Sep 09 — IV 48% · EM ±6.0%Sep 10 — IV 41% · EM ±4.9%Sep 11 — IV 44% · EM ±4.9%Sep 14 — IV 60% · EM ±5.1%Sep 15 — IV 74% · EM ±5.3%Sep 16 — IV 89% · EM ±5.2%Sep 17 — IV 99% · EM ±4.1%Sep 21 — IV 54% · EM ±11.2%Sep 22 — IV 53% · EM ±10.8%Sep 23 — IV 54% · EM ±10.8%Sep 24 — IV 56% · EM ±11.0%Sep 25 — IV 55% · EM ±10.6%Sep 28 — IV 55% · EM ±9.8%Sep 29 — IV 53% · EM ±9.2%Sep 30 — IV 57% · EM ±9.5%Oct 01 — IV 57% · EM ±9.2%Oct 02 — IV 64% · EM ±9.9%Oct 06 — IV 57% · EM ±7.6%Oct 07 — IV 70% · EM ±8.8%Oct 08 — IV 52% · EM ±6.2%

Sector peers

CORT
Corcept Therapeutics Incorporated
$12.9B $85.86-26.2%
ELAN
Elanco Animal Health Incorporated
$11.2B $22.51-0.2%
RDY
Dr. Reddy's Laboratories Ltd
$10.2B $13.190.0%
SMMT
Summit Therapeutics Inc.
$14.4B $15.47-2.3%
NUVL
Nuvalent, Inc.
$9.8B $123.96
ASND
Ascendis Pharma A/S
$15.0B $243.37+1.9%

ARWR earnings FAQ

What is ARWR's expected move for earnings?

Options currently price a move of about ±6.2%, or $3.58 per share either way from $58.02.

How does ARWR stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.4%, up 1 times and down 1 times.

What is ARWR's implied volatility?

ARWR's at-the-money implied volatility is about 52% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in